Followers | 1337 |
Posts | 259258 |
Boards Moderated | 57 |
Alias Born | 12/07/2009 |

Friday, June 14, 2024 9:29:21 AM
Renovaro Inc
Fri, Jun 14, 2024, 9:06 AM EDT
In this article:
RENB
+1.40%
Renovaro Inc
LOS ANGELES, June 14, 2024 (GLOBE NEWSWIRE) -- Renovaro, Inc. (NASDAQ: RENB) (the “Company”) announces that it has $10 million in additional equity committed at a price per share of $1.4726 and 10 percent warrant coverage.
“We appreciate confidence in the Company demonstrated by the investors,” said the Hon. Mark Dybul, MD, CEO. “We believe this is only the beginning. We are hopeful to be able to secure additional financing such as, but not limited to, long-term loans, grants and subsidies from various US and European institutions for which the Company is eligible – potentially worth tens of millions of dollars.”
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline and platform. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Renovaro’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Renovaro Inc. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
For media inquiries, please contact: karen@renovarocube.com
Source: Renovaro Inc.

ALL posts are opinions only. Any investments, trades, speculations, or decisions made on the basis of any information posted are committed at your own risk.
Disclaimer
Recent RENB News
- Renovaro Secures High-Powered Computing from Nebul Through a Partnership to Accelerate Next-Generation Biomarker Discovery and Diagnostic Programs • GlobeNewswire Inc. • 04/22/2025 01:20:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/18/2025 09:00:41 PM
- Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 04/15/2025 01:46:44 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/10/2025 08:55:50 PM
- Renovaro and BioSymetrics Close Merger to Accelerate AI-Driven Biomarker Discovery and Precision Medicine • GlobeNewswire Inc. • 04/09/2025 01:25:00 PM
- Renovaro Provides Update to Definitive Agreement with Predictive Oncology • GlobeNewswire Inc. • 04/04/2025 01:40:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/12/2025 12:12:50 PM
- Renovaro Completes First Milestone Payment to Finalize Definitive Agreement with Predictive Oncology • GlobeNewswire Inc. • 03/03/2025 02:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2025 09:05:41 PM
- Renovaro and BioSymetrics Announce Definitive Merger Agreement to Advance AI-Driven Biomarker Discovery and Precision Medicine • GlobeNewswire Inc. • 02/26/2025 06:25:00 PM
- Renovaro Announces $15 million in Equity Committed • GlobeNewswire Inc. • 02/26/2025 02:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/25/2025 06:33:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/25/2025 06:29:46 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/19/2025 09:02:47 PM
- Investors Eye Biotech Sector as Cancer Therapy Market Surges • PR Newswire (US) • 02/19/2025 03:10:00 PM
- Investors Eye Biotech Sector as Cancer Therapy Market Surges • PR Newswire (US) • 02/19/2025 03:06:00 PM
- Investors Eye Biotech Sector as Cancer Therapy Market Surges • PR Newswire (Canada) • 02/19/2025 03:06:00 PM
- Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend] • Edgar (US Regulatory) • 02/19/2025 02:00:38 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 02/19/2025 01:55:44 PM
- Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend] • Edgar (US Regulatory) • 02/19/2025 01:50:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/19/2025 01:45:21 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 02/18/2025 09:51:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/10/2025 09:05:12 PM
Coeptis Therapeutics, Inc. and Z Squared Inc. Announce Merger Agreement • COEP • Apr 25, 2025 8:33 AM
UAV Corp. Successfully Completes Inflation Test of DART SA-70 Airship, Paving Way for Flight Readiness • UMAV • Apr 24, 2025 8:30 AM
InnerScope Hearing Technologies (OTC: INND) Announces the Grand Opening of OTCHealthMart.com • INND • Apr 24, 2025 8:00 AM
Opus Holdings Unveils Powerhouse Leadership Team to Drive Aggressive Growth and Transform Market Trajectory • CATV • Apr 22, 2025 8:30 AM
Glidelogic Corp. (OTCQB: GDLG) Highlights Independent SOTA Evaluation of ResearchMind Platform • GDLG • Apr 22, 2025 6:54 AM
UAV Corp to Launch Inflation Test of SA-70 Airship This Week-A Gateway to High-Value Government and Defense Contracts • UMAV • Apr 21, 2025 1:30 PM